

25 March 2014 EMA/HMPC/321233/2012 Corr.1 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on Panax ginseng C.A.Meyer, radix

Final

Discussion in Working Party on Community monographs and Community	May 2012
list (MLWP)	November 2012
	January 2013
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	12 March 2013
for consultation	12 March 2013
End of consultation (deadline for comments)	15 July 2013
Rediscussion in Working Party on Community monographs and	September 2013
Community list (MLWP)	November 2013
	January 2014
Adoption by Committee on Herbal Medicinal Products (HMPC)	25 March 2014

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional	
	use; Panax ginseng C.A. Meyer, radix; Ginseng radix, Ginseng root	

BG (bălgarski): Жен-шен, корен		
CS (čeština): všehojový kořen		
DA (dansk): Ginsengrod		
DE (Deutsch): Ginsengwurzel		
EL (elliniká): γἰνσεγκ πἀναξ		
EN (English): ginseng root		
ES (espanol): Ginseng, raíz de		
ET (eesti keel): ženšennijuur		
FI (suomi): ginseng, juuri		
FR (français): Ginseng (racine de)		
115 /1 1 1 2 01 1 11		

HR (hrvatska) Ginsengov korijen HU (magyar): Ginzenggyökér IT (italiano): Ginseng radice

LT (lietuvių kalba): Ženšenių šaknys LV (latviešu valoda): Žeņšeņa saknes MT (malti): Gherq ta' I-Ġinseng NL (nederlands): Ginseng

PL (polski): Korzeń żeń-szenia

PT (português): Ginseng

RO (română): rădăcină de ginseng SK (slovenčina): Ženšenový koreň

SL (slovenščina): korenina pravega ženšena

(ginsenga)

SV (svenska): Ginsengrot

IS (íslenska):

NO (norsk): Ginsengrot



¹ Correction under 4.2 Posology, point I

Community herbal monograph on Panax ginseng C.A. Meyer, radix

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition $^{2,\;3}$

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Panax ginseng C.A. Meyer, radix (Ginseng root)
	i) Herbal substance Not applicable.
	ii) Herbal preparations
	White ginseng:
	A) Comminuted herbal substance
	B) Powdered herbal substance
	C) Dry extract (DER 2-7:1), extraction solvent ethanol 34-40% V/V
	D) Dry extract (DER 3-7:1), extraction solvent ethanol 40% V/V, containing 4% ginsenosides (sum of Rb ₁ , Rb ₂ , Rc, Rd, Re, Rf, Rg ₁ , Rg ₂)
	E) Dry extract (DER 3-7:1), extraction solvent ethanol 57.9% V/V (=50% m/m)-60% V/V
	F) Dry extract (DER 3.3-5:1), extraction solvent methanol 60% V/V
	G) Soft extract (DER 1.7-3.2:1), extraction solvent ethanol 60%-70% V/V
	H) Soft extract (DER 2-6:1), extraction solvent methanol 30% V/V
	I) Liquid extract (DER 1: 0.8-1.2), extraction solvent ethanol 30.5% V/V (=25% m/m) – 34% V/V
	J) Liquid extract (DER 1:11-13.6), extraction solvent liquor wine

² The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. ³ The material complies with the Ph. Eur. monograph (ref.: 7.0/1523)

Well-established use	Traditional use
	Red Ginseng:
	K) Powdered herbal substance
	L) Dry extract (DER 2-4.5:1), extraction solvent ethanol 60% V/V

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance (herbal preparation A) as herbal tea for oral use.
	Herbal preparations F, K, L in solid dosage forms for oral use.
	Herbal preparations G, H, I, J in liquid dosage forms for oral use.
	Herbal preparation B, C, D, E in solid and liquid dosage forms.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product for symptoms of asthenia such as fatigue and weakness.
	The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration⁴

Well-established use	Traditional use
	Posology
	Adults and elderly
	White ginseng:
	A) Comminuted herbal substance:

 $^{^4}$ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Tra	nditional use
		Herbal tea: 1000-2000 mg of the comminuted herbal substance in 150 ml of water as a decoction 2-3 times daily
	B)	Powdered herbal substance
		Single dose: 250-1200 mg Daily dose: 600-2000 mg Dosage frequency: once daily (1200 mg), 2-8 times daily
	C)	Dry extract (DER 2-7:1), extraction solvent ethanol 34-40% V/V
		Single dose: 90-360 mg Daily dose: 200-670 mg Dosage frequency: 1-4 times daily
	D)	Dry extract (DER 3-7:1), extraction solvent ethanol 40% V/V, containing 4% ginsenosides (sum of Rb ₁ , Rb ₂ , Rc, Rd, Re, Rf, Rg ₁ , Rg ₂)
		Single dose: 40-200 mg Daily dose: 40-200 mg (can be increased up to 600 mg in the first 5 days in special situations) Dosage frequency: 1-2 times daily
	E)	Dry extract (DER 3-7:1), extraction solvent ethanol 57.9 % V/V (=50% m/m) - 60% V/V
		Single dose: 98-220 mg Daily dose: 196-525 mg Dosage frequency: 2-4 times daily
	F)	Dry extract (DER 3.3-5:1), extraction solvent methanol 60% V/V
		Single dose: 120 mg Daily dose: 360 mg Dosage frequency: 3 times daily
	G)	Soft extract (DER 1.7-3.2:1), extraction solvent ethanol 60%-70% V/V
		Single dose: 300-440 mg Daily dose: 440-700 mg Dosage frequency: once daily (440 mg) or 2 times daily
	H)	Soft extract (DER 2-6:1), extraction solvent methanol 30% V/V
		Single dose: 219.8 mg Daily dose: 439.6 mg

Well-established use	Traditional use	
	Dosage frequency: 2 times daily	
	I) Liquid extract (DER 1:0.8-1.2), ethanol 30.5% V/V (=25% m/m) - 34% V/V	
	Single dose: 500 mg - 1250 mg Daily dose: 900 mg – 2500 mg Dosage frequency: 1-2 times daily	
	J) Liquid extract (DER 1:11-13.6), extraction solvent liquor wine	
	Single dose: 19.4 ml Daily dose: 19.4 ml Dosage frequency: once daily	
	Red ginseng:	
	K) Powdered herbal substance:	
	Single dose: 600 mg Daily dose: 1800 mg Dosage frequency: 3 times daily	
	L) Dry extract (DER 2-4.5:1), extraction solvent ethanol 60% V/V	
	Single dose: 180-500 mg Daily dose: 360-500 mg Dosage frequency: once daily (475 mg or 500 mg) or 2 times daily	
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use')	
	Duration of use	
	Duration of use up to 3 months. If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.	
	Method of administration	
	Oral use.	

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
Well-established use	Traditional use The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health
	care practitioner should be consulted. For extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
	No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Hypersensitivity reactions (urticaria, itching), insomnia and gastrointestinal disorders like stomach discomfort, nausea, vomiting, diarrhoea, and constipation have been reported. The frequency is not known.

Well-established use	Traditional use
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
Well-established use	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. No signs of genotoxicity were observed in an AMES-test (Salmonella typhimurium strains TA 1535, TA 1537, TA 1538, TA 98 and TA 100) with and without metabolic activation using an extract prepared with ethanol 40% V/V (herbal preparation D). This was confirmed with an extract prepared with ethanol 80% in a guideline-conform AMES-test (OECD-471) with and without metabolic activation as well as in a micronucleus
	test. After 2 years of oral administration of an extract prepared with ethanol 80% in dosages of up to 5000 mg/kg b.w. no signs of carcinogenicity were observed in mice or rats.

Well-established use	Traditional use
	Adequate tests on reproductive toxicity have not
	been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

25 March 2014